1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Sir Andrew Witty
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2781
|
7 (partnership shares)
|
||
£17.2781
|
7 (matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
14 Ordinary Shares
£17.2781
|
|
e)
|
Date
of the transaction
|
2016-10-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R G Connor
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2781
|
7 (partnership shares)
|
||
£17.2781
|
7 (matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
14 Ordinary Shares
£17.2781
|
|
e)
|
Date
of the transaction
|
2016-10-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr S Dingemans
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2781
|
7 (partnership shares)
|
||
£17.2781
|
7 (matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
14 Ordinary Shares
£17.2781
|
|
e)
|
Date
of the transaction
|
2016-10-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2781
|
8 (partnership shares)
|
||
£17.2781
|
8 (matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
16 Ordinary Shares
£17.2781
|
|
e)
|
Date
of the transaction
|
2016-10-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr S A Hussain
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2781
|
7 (partnership shares)
|
||
£17.2781
|
7 (matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
14 Ordinary Shares
£17.2781
|
|
e)
|
Date
of the transaction
|
2016-10-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D S Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2781
|
8 (partnership shares)
|
||
£17.2781
|
8 (matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
16 Ordinary Shares
£17.2781
|
|
e)
|
Date
of the transaction
|
2016-10-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms C Thomas
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2781
|
8 (partnership shares)
|
||
£17.2781
|
8 (matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
16 Ordinary Shares
£17.2781
|
|
e)
|
Date
of the transaction
|
2016-10-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr P C Thomson
|
|
b)
|
Position/status
|
SVP, Communications & Government Affairs
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2781
|
7 (partnership shares)
|
||
£17.2781
|
7 (matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
14 Ordinary Shares
£17.2781
|
|
e)
|
Date
of the transaction
|
2016-10-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Dr P J T Vallance
|
|
b)
|
Position/status
|
President, Pharmaceuticals R&D
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2781
|
7 (partnership shares)
|
||
£17.2781
|
7 (matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
14 Ordinary Shares
£17.2781
|
|
e)
|
Date
of the transaction
|
2016-10-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
CEO Designate
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2781
|
8 (partnership shares)
|
||
£17.2781
|
8 (matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
16 Ordinary Shares
£17.2781
|
|
e)
|
Date
of the transaction
|
2016-10-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mrs V A Whyte
|
|
b)
|
Position/status
|
Company Secretary
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2781
|
7 (partnership shares)
|
||
£17.2781
|
7 (matching shares)
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
14 Ordinary Shares
£17.2781
|
|
e)
|
Date
of the transaction
|
2016-10-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|